Table. 1 Demographic characteristics of the studies included
From: Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
Study, year | Location | Treatment arm (n) | HbA1c(%) | Male (n) | Age (years) | BMI (kg/m2) | Diabetes duration (years) | Treatment duration (months) | Leptin (ng/mL) |
|---|---|---|---|---|---|---|---|---|---|
Takeshita [37] | Japan | Sitagliptin:28 Mitiglinide:29 | 6.7 ± 0.6 6.9 ± 0.8 | 18 19 | 61.0 ± 13.8 65.8 ± 9.7 | 24.5 ± 3.8 24.2 ± 4.6 | 86.4 ± 90 145.2 ± 122.4 | 4 | 8.7 ± 6.5 10.5 ± 13.4 |
Takeshita [38] | Japan | Vildagliptin:53 Liraglutide:49 | 8.1 ± 1.2 8.0 ± 0.9 | 36 35 | 64.5 ± 12.7 64.9 ± 1.9 | 24.5 ± 4.6 25.4 ± 4.8 | NS | 3 | 8.1 ± 6.9 6.9 ± 5.7 |
Kato [39] | Japan | Sitagliptin:10 Glimepiride:10 | 7.2 ± 0.2 7.3 ± 0.2 | 6 5 | 62 ± 4.7 55 ± 6.7 | 25.6 ± 2.6 26.6 ± 2.5 | NS | 6 | 12.6 ± 2.3 10.3 ± 3.0 |
Matsushima [40] | Japan | Sitagliptin: 120 Voglibose:121 | 7.9 ± 1.0 7.8 ± 0.8 | 72 71 | 63.2 ± 13.8 63.2 ± 11.6 | 25.0 ± 4.5 25.1 ± 4.5 | NS | 3 | 8.3 ± 6.9 9.0 ± 9.3 |
Dore [41] | American | Saxagliptin:21 Placebo:21 | 7.0 ± 0.8 6.6 ± 0.5 | 10 14 | 58.3 ± 5.7 56.4 ± 8.5 | 32.3 ± 4.2 31.5 ± 4.8 | 120 | 3 | 19.4 ± 3.7 14.1 ± 2.1 |
Takihata [42] | Japan | Sitagliptin:17 Luseogliflozin:17 | 10.0 ± 1.41 0.4 ± 1.0 | 14 15 | 52.8 ± 15.5 52.1 ± 15.3 | 26.8 ± 5.1 26.4 ± 4.8 | NS | 3 | 9.1 ± 6.7 7.2 ± 4.7 |
Takeshita [43] | Japan | Alogliptin:42 Metfomin:42 | 7.5 ± 1.07 .4 ± 1.2 | 29 29 | 63.8 ± 10.5 63.1 ± 13.1 | 25.4 ± 6.1 24.4 ± 4.0 | 122.4 ± 124.8 169.2 ± 156 | 3 | 11.2 ± 12.8 8.4 ± 10.7 |
Schiapaccassa [44] | Brazil | Vildagliptin:19 Metformin:19 | 8.0 ± 1.8 7.9 ± 2.0 | 0 0 | 39.1 ± 5.3 39.8 ± 7.7 | 36.0 ± 4.0 38.5 ± 6.1 | NS | 1 | 21.9 ± 19.4 25.4 ± 13.3 |
Awal [45] | American | Linagliptin:14 Placebo:17 | 7.1 ± 0.7 7.4 ± 1.0 | 11 7 | 61.0 ± 5.0 63.0 ± 6.0 | 31.2 ± 4.4 30.6 ± 2.9 |  ≤ 180 | 3 | 21.7 ± 22.8 22.5 ± 12.6 |
Komorizono [46] | Japan | Linagliptin:24 Metformin:25 | 7.0 ± 0.5 7.2 ± 0.8 | 10 9 | 49.4 ± 10.8 55.6 ± 10.2 | 29.7 ± 4.9 27.9 ± 4.1 | NS | 13 | 17.7 ± 9.3 18.5 ± 8.2 |